Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1632 1651 1683
This examiner grants 51% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17919677 | CLEARANCE OF SENESCENT CELLS BY ACTIVATION OF iNKT CELLS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17799851 | Regulating Activation of Fibroblasts to Prevent Fibrosis | Non-Final OA | The Regents of the University of California |
| 17795735 | Elimination of BCMA-positive malignancies by CAR expressing NK cells | Final Rejection | ImmunityBio, Inc. |
| 17180506 | System and Method for Organ Maintenance and Transport | Final Rejection | DEKA Products Limited Partnership |
| 18022234 | Materials for Tumor Inoculation in Murine Mouse Models and Uses Thereof | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17838428 | MODULATION OF UBIQUITIN CARBOXY-TERMINAL HYDROLASE LIGASE 1 (UCHL1) EXPRESSION FOR TREATING NEUROLOGICAL DISEASE, DISORDERS, AND INJURIES ASSOCIATED WITH UPPER MOTOR NEURONS | Final Rejection | Northwestern University |
| 17959327 | CANNABIDIOL-CONTAINING COMPOSITIONS AND USES THEREOF | Non-Final OA | Ramot at Tel-Aviv University Ltd. |
| 19208449 | BIOLOGICAL TISSUE AND METHOD OF MANUFACTURING | Final Rejection | BioCreations Medical, LLC |
| 19194137 | USE OF HUMAN UMBILICAL CORD MESENCHYMAL STEM CELL-DERIVED EXOSOMES (hUC-MSC-ES) | Final Rejection | BEIJINGANZHEN HOSPITAL,CAPITALMEDICAL UNIVERSITY |
| 17611500 | TREATMENT OF ISCHEMIC STROKE WITH APTAMERS TARGETING TLR-4 | Non-Final OA | Merck Patent GmbH |
| 18024091 | METHODS FOR REPROGRAMMING TARGET CELLS | Non-Final OA | Duke University |
| 17053422 | STEM CELL-DERIVED CELL CULTURES, STEM CELL-DERIVED THREE DIMENSIONAL TISSUE PRODUCTS, AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | The Regents of the University of Colorado, A Body Corporate |
| 18000706 | ENCODING AND EXPRESSION OF ACE-tRNAs | Non-Final OA | University of Rochester |
| 17407604 | Cardiac Muscle-Cell-Based Coupled Oscillator Network for Collective Computing and Related Methods | Final Rejection | University of Virginia Patent Foundation |
| 18025036 | Complex Containing Neural Retina-Containing Cell Aggregates and Matrix, and Method for Manufacturing Same | Non-Final OA | Sumitomo Pharma Co., Ltd. |
| 18021596 | 3D NEURONAL TISSUE GRAFTS USING ULTRASHORT SELF-ASSEMBLING PEPTIDE SCAFOLDS | Non-Final OA | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY |
| 18281154 | STEM CELL DIFFERENTIATION AND POLYMERS | Non-Final OA | VERTEX PHARMACEUTICALS INCORPORATED |
| 18133237 | MEDIA COMPOSITIONS FOR NEURONAL CELL CULTURE | Final Rejection | SALK INSTITUTE FOR BIOLOGICAL STUDIES |
| 18533611 | METHOD FOR CULTURING 3-DIMENSIONAL LUNG CANCER ORGANOID AND METHOD FOR PREPARING PATIENT-DERIVED XENOGRAFT ANIMAL MODEL USING SAME | Non-Final OA | SG MEDICAL, INC. |
| 17260754 | IMPLANTS TO INDUCE BONE REGENERATION AND USES THEREOF | Non-Final OA | University of lowa Research Foundation |
| 18555198 | SAFE HARBOR LOCI FOR CELL ENGINEERING | Non-Final OA | HANGZHOU QIHAN BIOTECH CO., LTD. |
| 18371694 | APPARATUS AND METHOD FOR INDUCING HUMAN OOCYTE MATURATION IN VITRO | Final Rejection | Gameto, Inc. |
| 17745016 | CELLULAR TARGETED PHARMACEUTICALLY ACTIVE SUBSTANCE OR LABEL DELIVERY SYSTEM | Final Rejection | CELLIS AG |
| 17922119 | COMPOSITIONS AND METHODS FOR TREATMENT OF INHERITED MACULAR DEGENERATION | Non-Final OA | Blue Marlin Therapeutics, Inc. |
| 18033629 | MESENCHYMAL STEM CELLS AND THEIR CULTURE | Non-Final OA | NEUROGENESIS LTD. |
| 18009231 | METHOD OF MANUFACTURING MICRODEVICES FOR LAB-ON-CHIP APPLICATIONS | Non-Final OA | Wageningen Universiteit |
| 17816998 | COMPOSITION FOR BONE REGENERATION CONTAINING HYDROGEL AND STEM CELL SPHEROID, AND USE THEREOF | Final Rejection | SELJIN CO.LTD. |
| 17773422 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | Non-Final OA | Magenta Therapeutics, Inc. |
| 17640378 | TREATING MITOCHONDRIAL DNA DEPLETION DISORDERS | Final Rejection | MITORAINBOW THERAPEUTICS, INC. |
| 16900719 | IN VITRO AVIAN FOOD PRODUCT | Non-Final OA | GOOD Meat, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy